Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

Phase 2 Study of Oral IXAZOMIB in Adult Participants With Relapsed and/or Refractory Follicular Lymphoma

7. oktober 2019 opdateret af: Millennium Pharmaceuticals, Inc.

An Open-label, Multicenter, Phase 2 Study of Oral IXAZOMIB (MLN9708) in Adult Patients With Relapsed and/or Refractory Follicular Lymphoma

The primary purpose of this study is to evaluate the anti-tumor activity of oral Ixazomib as measured by overall response rate (ORR) in adult participants with relapsed and/or refractory follicular lymphoma (FL).

Studieoversigt

Status

Afsluttet

Betingelser

Intervention / Behandling

Undersøgelsestype

Interventionel

Tilmelding (Faktiske)

29

Fase

  • Fase 2

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiesteder

  • Belgien
      • Gent, Belgien
      • Leuven, Belgien
      • Wilrijk, Belgien
  • Canada
    • Quebec
      • Montreal, Quebec, Canada
  • Det Forenede Kongerige
      • London, Det Forenede Kongerige
      • Manchester, Det Forenede Kongerige
      • Newcastle Upon Tyne, Det Forenede Kongerige
      • Plymouth, Det Forenede Kongerige
      • Southampton, Det Forenede Kongerige
      • Sutton, Det Forenede Kongerige
  • Forenede Stater
    • Massachusetts
      • Boston, Massachusetts, Forenede Stater
    • New York
      • New York, New York, Forenede Stater
    • Tennessee
      • Nashville, Tennessee, Forenede Stater
    • Texas
      • Houston, Texas, Forenede Stater

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år og ældre (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Male or female participants 18 years or older.
  • Participants must have a pathologically confirmed diagnosis of non-Hodgkin lymphoma (NHL) (for the lead-in dose-finding phase) and FL (for phase 2).
  • Participants must have radiographically or clinically measurable disease.
  • Participants must be relapsed and/or refractory after at least 1 prior therapy (excluding radiation) with documented progressive disease at the time of enrollment.
  • Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 2.
  • Female participants who are post menopausal, surgically sterile, or agree to practice 2 effective methods of contraception or agree to practice true abstinence.
  • Male participants who agree to practice effective barrier contraception or agree to practice true abstinence.
  • Voluntary written consent.
  • Suitable venous access.
  • Appropriate clinical laboratory values as defined in the protocol.
  • Recovered from toxicities of prior anticancer therapy.
  • If the trial proceeds to the second step on the basis of the tandem 2-step design, participants must be confirmed PSMB1 positive at the central laboratory before treatment.

Exclusion Criteria

  • Peripheral neuropathy that is greater or equal to Grade 2 or Grade 1 with pain.
  • Female participants who are lactating and breastfeeding or have a positive serum pregnancy test during the Screening period.
  • Autologous stem cell transplant within 6 months before Day 1 of Cycle 1, or prior allogeneic stem cell transplant at any time.
  • Major surgery within 14 days before the first dose of study drug.
  • Infection requiring systemic antibiotic therapy or other serious infection within 14 days before the first dose of study drug.
  • Comorbid systemic illnesses or other severe concurrent disease that, in the judgment of the investigator, would make the participants inappropriate for entry into this study or interfere significantly with the proper assessment of safety and toxicity of the prescribed regimens.
  • Evidence of current uncontrolled cardiovascular conditions including uncontrolled hypertension, severe uncontrolled ventricular arrhythmias, unstable angina, New York Heart Association (NYHA) Class III or IV cardiac disease, or myocardial infarction within the past 6 months.
  • Diarrhea greater than (>) Grade 1 on the basis of the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI CTCAE) categorization.
  • Systemic antineoplastic (including glucocorticoids > the equivalent of 15 mg of prednisone daily), experimental, or radiation therapy within 21 days before the first dose of study drug.
  • Prior treatment with rituximab or other unconjugated antibody treatment within 42 days (21 days if clear evidence of progressive disease or immediate treatment is mandated).
  • Treatment with radioimmunoconjugates or toxin immunoconjugates within 12 weeks before the first dosing of study treatment.
  • Systemic treatment with strong inhibitors of Cytochrome P450 1A2 (CYP1A2) or Cytochrome P450 3A (CYP3A), or strong CYP3A inducers within 14 days before the first dose of IXAZOMIB - Ongoing systemic therapy with corticosteroids.
  • Central nervous system (CNS) involvement that is clinically uncontrolled or newly diagnosed in the last 4 months.
  • Ongoing or active systemic viral infection, known human immunodeficiency virus (HIV) positive, known active hepatitis B virus or known active hepatitis C virus.
  • Diagnosed or treated for another malignancy within 2 years before study enrollment or previously diagnosed with another malignancy and have any evidence of residual disease with the exception of nonmelanoma skin cancer or any completely resected carcinoma in situ.
  • Platelet transfusions within 3 days before the 1st dose of study drug.
  • Inability to swallow capsules, or inability or unwillingness to avoid taking anything by mouth except for water and prescribed medication for 2 hours before and 1 hour after dose of IXAZOMIB - Known allergy to boron or excipients in the formulation.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: IXAZOMIB
Ixazomib 4, 5.3 and 7 milligram (mg), orally, once on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days, for up to Cycle 29 or until disease progression or unacceptable toxicity at lead-in phase for participants with NHL. After completion of lead-in phase, participants will continue into Phase 2. Participants in Phase 2 will receive Ixazomib at RP2D dose, orally, once weekly on Days 1, 8 and 15 in a 28 day treatment cycle followed by a rest period of 13 days , for up to Cycle 29 or until disease progression or unacceptable toxicity in Phase 2 for participants with RRFL.
Medicin: IXAZOMIB
Each 28-day treatment cycle will include oral administration of IXAZOMIB on Days 1, 8, and 15 followed by a rest period of 13 days.
Andre navne:
  • MLN9708

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Number of Participants With Overall Response Rate (ORR)
Tidsramme: Baseline up to Day 15 Cycle 29 (approximately up to Day 802) or until PD or the start of alternate therapies
ORR is defined as the percentage of participants with complete response (CR) or partial response (PR) as assessed by the investigator using the international Working Group criteria for participants CR: disappearance of all target lesions, non-target lesions, no new lesions, and normalization of tumor marker level. PR: At least a 30 percent (%) decrease in the sum of diameters of target lesions, no progression in non-target lesion, and no new lesions.
Baseline up to Day 15 Cycle 29 (approximately up to Day 802) or until PD or the start of alternate therapies

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Lead-in Dose Finding Phase: Recommended Phase 2 Dose (RP2D)
Tidsramme: Baseline up to Cycle 1 Day 28
Baseline up to Cycle 1 Day 28
Progression Free Survival (PFS)
Tidsramme: Time from the date of first dose of study treatment to the date of first documented PD or death (approximately up to Day 802)
PFS is defined as the time from the date of first dose of study treatment to the date of first documented PD or death. Participants without documentation of PD will be censored at the date of last response assessment that is SD or better. Participants without response assessment will be censored at the date of first dose.
Time from the date of first dose of study treatment to the date of first documented PD or death (approximately up to Day 802)
Phase 2: Rate of Disease Control
Tidsramme: Baseline or until occurrence of disease progression, unacceptable toxicities, or discontinuation of study due to any other reasons (approximately up to Day 805)
Rate of disease control is defined as percentage of participants who achieved a SD or better for greater than or equal to (>=) 6 months.
Baseline or until occurrence of disease progression, unacceptable toxicities, or discontinuation of study due to any other reasons (approximately up to Day 805)
Time to Response (TTR)
Tidsramme: Time from the date of first dose of study treatment to the date of first documented PR or better response or death (approximately up to Day 802)
TTR is defined as the time from the date of first dose of study treatment to the date of the first documentation of a PR or better response in a participant who responded.
Time from the date of first dose of study treatment to the date of first documented PR or better response or death (approximately up to Day 802)
Duration of Response (DOR)
Tidsramme: Time from the date of first documentation of a response to the date of first documented PD (approximately up to Day 802)
The DOR is defined as the time from the date of first documentation of a response to the date of first documented PD. Responders without documentation of PD will be censored at the date of last response assessment. DOR was categorized as CR+PR and CR.
Time from the date of first documentation of a response to the date of first documented PD (approximately up to Day 802)
Phase 2: Number of Participants With Response Rates in PSMB1 Positive and PSMB1 Negative
Tidsramme: Baseline up to occurrence of disease progression, unacceptable toxicities, or discontinuation of study due to any other reasons (approximately up to Day 802)
Baseline up to occurrence of disease progression, unacceptable toxicities, or discontinuation of study due to any other reasons (approximately up to Day 802)
Number of Participants Experiencing 1 or More Treatment-Emergent Adverse Events (TEAEs) and Serious Adverse Events (SAEs)
Tidsramme: Baseline up to 30 days after last dose of study drug (approximately up to Day 832)
Baseline up to 30 days after last dose of study drug (approximately up to Day 832)
Lead-in Dose Finding Phase: Cmax: Maximum Observed Plasma Concentration for Ixazomib
Tidsramme: Cycle 1, Days 1 and 15 pre-dose and at multiple time points (up to 168 hours) post-dose
Cycle 1, Days 1 and 15 pre-dose and at multiple time points (up to 168 hours) post-dose
Lead-in Dose Finding Phase: Tmax: Time to Reach the Maximum Plasma Concentration (Cmax) for Ixazomib
Tidsramme: Cycle 1, Days 1 and 15 pre-dose and at multiple time points (up to 168 hours) post-dose
Cycle 1, Days 1 and 15 pre-dose and at multiple time points (up to 168 hours) post-dose
Lead-in Dose Finding Phase: AUC(0-168): Area Under the Plasma Concentration-time Curve From Time 0 to 168 Hours Postdose for Ixazomib
Tidsramme: Cycle 1, Days 1 and 15 pre-dose and at multiple time points (up to 168 hours) post-dose
Cycle 1, Days 1 and 15 pre-dose and at multiple time points (up to 168 hours) post-dose

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Millennium Pharmaceuticals, Inc.

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Faktiske)

31. oktober 2013

Primær færdiggørelse (Faktiske)

1. juni 2016

Studieafslutning (Faktiske)

23. marts 2017

Datoer for studieregistrering

Først indsendt

28. august 2013

Først indsendt, der opfyldte QC-kriterier

6. september 2013

Først opslået (Skøn)

11. september 2013

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

29. oktober 2019

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

7. oktober 2019

Sidst verificeret

1. oktober 2019

Mere information

Begreber relateret til denne undersøgelse

Nøgleord

Yderligere relevante MeSH-vilkår

Andre undersøgelses-id-numre

  • C16017
  • 2013-002302-32 (EudraCT nummer)
  • U1111-1164-7551 (Anden identifikator: WHO)
  • 166547 (Registry Identifier: HC-CTD)
  • REec-2016-2137 (Registry Identifier: REec)
  • 13/EM/0373 (Registry Identifier: NRES)

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Kliniske forsøg med Follikulært lymfom

Kliniske forsøg med IXAZOMIB

Søg i lignende forsøg

Sponsorer og samarbejdspartnere

Medicinske tilstande

Narkotikainterventioner

CROs by country

CROs in Georgia

Betingelser

Sjældne sygdomme

Narkotikainterventioner

Kosttilskud

Sponsor / samarbejdspartnere

Placeringer

Abonner